^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Anboni (unecritinib)

    i
    Company:
    Sino Biopharm
    Drug class:
    ALK inhibitor, ROS1 inhibitor, c-MET inhibitor
    Related drugs:
    Apply
    A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL) (TQ-B3101-II-02) (NCT04306887)
    Phase 2
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Recruiting
    Last update posted :
    03/13/2020
    Initiation :
    11/29/2019
    Primary completion :
    12/31/2022
    Completion :
    12/31/2022
    ALK
    |
    ALK positive
    |
    Anboni (unecritinib)
    Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (NCT03972189)
    Phase 2
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Unknown status
    Last update posted :
    08/15/2019
    Initiation :
    07/24/2019
    Primary completion :
    03/01/2021
    Completion :
    03/01/2021
    ROS1
    |
    ROS1 positive
    |
    Anboni (unecritinib)